| Serial Number | 79381492 |
| Word Mark | PLEQSTIBA |
| Filing Date | Friday, September 1, 2023 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, October 1, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 1, 2024 |
| Goods and Services | Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events (MACE) in patients within 90 days of an acute myocardial infarction (AMI) with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction (AMI); Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, October 20, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | CSL Behring AG |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 25 - NOT AVAILABLE |
| Address | CH |
| Party Name | CSL Behring AG |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 25 - NOT AVAILABLE |
| Address | CH |
| Event Date | Event Description |
| Thursday, October 19, 2023 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, October 20, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, October 24, 2023 | APPLICATION FILING RECEIPT MAILED |
| Friday, February 16, 2024 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Tuesday, April 30, 2024 | ASSIGNED TO EXAMINER |
| Monday, May 6, 2024 | NON-FINAL ACTION WRITTEN |
| Tuesday, August 27, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, August 27, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, August 27, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, August 27, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, September 11, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, October 1, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, October 1, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Monday, June 3, 2024 | REFUSAL PROCESSED BY IB |
| Tuesday, May 7, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, May 16, 2024 | REFUSAL PROCESSED BY MPU |
| Thursday, May 16, 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |